Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Overall investment in the US facility is estimated around US$50 million
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Subscribe To Our Newsletter & Stay Updated